At the University of Tokyo, scientists have turned stem cells into a working model of the human intestine — and through it, found that a compound long hidden in black licorice may hold new promise for the millions living with inflammatory bowel disease. Glycyrrhizin, drawn from a plant root with centuries of medicinal history, emerged from a screen of 3,500 candidates as a meaningful reducer of intestinal inflammation, performing well in both lab tissue and living mice. The finding matters not only for what it might offer IBD patients whose current treatments fall short, but for what it reveal
ScienceDaily
· May 10, 2026
· health
· 2 min de lectura
High
Verificación: Verificado
Black licorice compound shows promise in IBD treatment discovery
IBD affects approximately 4 million people worldwide with chronic symptoms including diarrhea, abdominal pain, and fatigue that significantly impact daily life.
◉
Health & Medicine
8293 artículos relacionados
Retatrutide: Eli Lilly's Triple-Action Weight-Loss Drug Poised to Resh…
The Economic Times · 100% coincidencia
Scientists identify toxic senescent cells in Alzheimer's brains as tre…
News-Medical.net · 99% coincidencia
Researchers uncover how bacteria survive antibiotics through tolerance…
News-Medical · 99% coincidencia
Mix-and-match COVID boosters offer immune system flexibility, expert e…
The Conversation · 99% coincidencia
FDA poised to approve scaled COVID vaccine for children ages 5-11
Futurity: Research News · 99% coincidencia
Cobertura Relacionada
7NEWS · Aug 23
Model's Foot Cut Led to Heart Surgery, Baby Loss—Now Advocating for Better Diagnostics
Australian model Leah Ramsey lost her baby after a small foot cut triggered a rare heart infection that was repeatedly m…
Informanté · Aug 23 South Africa Shares FMD Vaccines as Region Strengthens Disease ControlsSouth Africa reports its largest-ever FMD outbreak is coming under control through accelerated vaccination and regional …
Al Jazeera · Aug 23 Solar telemedicine kiosks expand healthcare access across rural ChadSolar-powered telemedicine kiosks in rural Chad enable remote doctor consultations at a fraction of traditional travel c…
Inquirer.net · Aug 23 Prince Harry returns to UK amid family rifts, seeking reconciliation with monarchyPrince Harry and Meghan Markle are relocating back to Britain after six years in California, potentially signaling recon…
Sesgo y Encuadre
⚖
Article presents promising IBD research with straightforward scientific reporting, minimal bias detected in presentation of stem cell study findings and glycyrrhizin results.
Bias Direction
center
Confidence
HIGH
Standard scientific discovery narrative emphasizing research methodology, problem-solution structure, and incremental progress toward medical treatment.
shows promise
emerges as a top candidate
strongest performers
Limitations or caveats of the research (gap between lab models and human trials)
Timeline for potential clinical application
Cost or accessibility considerations for future treatment
Perspectives from IBD patient advocacy groups
Competing or alternative treatment approaches in development
Potential side effects or safety concerns of glycyrrhizin
Impacto Geopolítico
🌎
Medical research on black licorice compound for IBD treatment has no direct geopolitical implications; purely scientific discovery with potential global health benefits.
Escalation Risk
low
Confidence
HIGH
Lente Económico
📈
Black licorice compound glycyrrhizin shows promise as IBD treatment, potentially creating new pharmaceutical market opportunities and reducing healthcare costs for 4M+ patients globally.
Market Signal
bullish
Confidence
MED
Pharmaceutical and biotechnology
Healthcare and medical devices
Natural products and nutraceuticals
Agricultural (licorice cultivation)
Potential new treatment option for IBD patients could reduce symptom burden, improve quality of life, and lower out-of-pocket costs if glycyrrhizin-based therapies prove cost-effective compared to existing immunosuppressants and biologics.
FDA approval pathway for novel IBD therapeutic could accelerate; potential regulatory framework for natural compound-derived pharmaceuticals; healthcare reimbursement discussions for new treatment class; possible agricultural subsidies for medicinal licorice production.